Among the few genetic events, frequent RAS mutations, as well as FLT3 mutations and/or overexpression, have long been recognized8–11; nevertheless, translational applicability of these aberrations as risk factors and/or therapeutic targets for infant ALL is still under debate5,8,12,13. Here, FLT3 is linked to acute lymphoblastic leukemia.